This phase 2 clinical trial will test the effectiveness of EPOCH, a 5-drug combination chemotherapy, with rituximab(Rituxan) in patients with certain types of non-Hodgkin's lymphoma. The primary outcome will be measured by the overall response and time to disease progression. This trial is being conducted in Maryland, in the United States.
EPOCH is a combination chemotherapy used to treat aggressive forms of non-Hodgkin’s lymphoma. This combination contains etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. Rituximab is an immunotherapy that uses the body’s own immune system to identify and kill cancerous B-cells. It is an antibody (a protein in the immune system) that binds to a protein found on B-cells, which alerts other parts of the immune system to attack.
The current study will examine the effectiveness of EPOCH combined with rituximab in untreated non-Hodgkin's lymphoma. The study will examine the overall response to the treatment and the time to disease progression.
Who are they looking for?
This trial is recruiting 348 patients, over the age of 12, who have not received prior systemic chemotherapy. Participants should have adequate organ function and be free of any non-related cancers for at least 5 years (with the exception of non-melanoma skin or in-situ cancers). Ideal candidates should not have symptomatic heart disease or congestive heart failure 1 year prior to enrollment.
How will it work
Patients will be administered EPOCH with rituximab intravenously (through IV) on day 1 of every 21-day cycle for 6 cycles.